Evotec invests €15m to further AI-driven drug discovery

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/monsitj)
(Image: Getty/monsitj)

Related tags: Drug discovery, Investment, Artificial intelligence

Evotec AG has acquired a minority stake in Exscientia – a company focused on artificial intelligence (AI)-driven drug discovery and design.

According to the company, the €15m ($17.63) investment will enable Exscientia to “drive higher value partner programs​” and expand discovery on its automated design platform.

As part of the transaction, Evotec’s Chief Operating Officer, Dr. Mario Polywka, will join Exscientia's Board of Directors.

The investment is the company’s largest single biggest equity placement to date, Dr. Werner Lanthaler, Evotec CEO explained in a press release.

The companies have worked together​ since 2016.

Working with Exscientia on a joint immuno-oncology project over the past year, we have experienced first-hand how its AI approaches, along with our medicinal chemistry platform, can positively and radically impact drug discovery​,” explained Lanthaler.

Exscientia, CEO, Prof. Andrew Hopkins added that the investment will allow Exscientia “to deliver more drug discovery projects in a rapid and capital efficient manner​.”

Related news

Show more

Related products

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers